A Phase 2 interventional study of Rituximab and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 92 sites in 16 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2017-03-13.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 7th largest by enrollment, is the only one that started in 2002, is one of 11 in phase 2, and was the 47th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 465 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 29th largest by enrollment of the 141 interventional ones that give a count, is the only one that started in 2002, is one of 20 in phase 2, and was the 186th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the long-term safety and efficacy of repeat treatment courses of rituximab, in combination with methotrexate in a disease-modifying anti-rheumatic drug (DMARD) inadequate responder population of participants who were previously randomized into studies WA16291 (NCT02693210) or WA17043/U2644g (NCT00074438). The study permits multiple re-treatments until the protocol-defined end-of-treatment date (31 December 2011). Participants will then enter a safety follow-up (SFU) period of at least 48 weeks. This will provide at least 7 years follow-up data on all participants initially randomized into WA16291 or WA17043/U2644g. Approximately 600 participants will potentially be eligible to enter this open label extension study from their respective feeder studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rituximab 1 gram intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants will receive methotrexate 10-25 milligrams per week (mg/week) orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid greater than or equal to (\>=) 5 mg/week or equivalent. Participants will receive retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first \[Day 1\] infusion of the last course of rituximab). Repeat treatment will be based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints \>=2.6). Retreatment with rituximab will be continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever is sooner.
Drug: Rituximab · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Folic Acid
Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
Also known as: MabThera, Rituxan
Participants will receive methotrexate 10-25 mg/week orally or parenterally.
Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
Participants will receive folic acid \>= 5 mg/week or equivalent.
Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response After First Course
A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in tender joint count (TJC) and swollen joint count (SJC) (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[visual analog scale (VAS): 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or erythrocyte sedimentation rate \[ESR\]). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
Time frame: 24 weeks after first course of rituximab (up to approximately 26 weeks)
Percentage of Participants With ACR20 Response After Second Course
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
Time frame: 24 weeks after second course of rituximab (median duration of 90.9 weeks)
Percentage of Participants With ACR20 Response After Third Course
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
Time frame: 24 weeks after third course of rituximab (median duration of 162.9 weeks)
Percentage of Participants With ACR20 Response After Fourth Course
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
Time frame: 24 weeks after fourth course of rituximab (median duration of 232 weeks)
Percentage of Participants With ACR20 Response After Fifth Course
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
Time frame: 24 weeks after fifth course of rituximab (median duration of 297.3 weeks)
Percentage of Participants With ACR20 Response After Sixth Course
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
Time frame: 24 weeks after sixth course of rituximab (median duration of 354.4 weeks)
Percentage of Participants With ACR20 Response After Seventh Course
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
Time frame: 24 weeks after seventh course of rituximab (median duration of 406.7 weeks)
Percentage of Participants With ACR50 and ACR70 Response
A participant had an ACR50 and ACR70 response if there was at least a 50% or 70% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of disease activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (CRP or ESR). The ACR50 and ACR70 responses were compared to Baseline in the precursor studies WA16291 or WA17043.
Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)
American College of Rheumatology Index of Improvement (ACRn) Response
The ACRn is calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (patient's assessment of disease activity; patient's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value \[either CRP or ESR\]). The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA. ACRn scores were calculated considering the original baseline in the precursor studies WA16291 or WA17043.
Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)
Percentage of Participants With Low Disease Activity and Clinical Remission Based on DAS28-ESR
DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (millimeters per hour \[mm/hour\]), and Patient's Global Assessment of Disease Activity (VAS: 0=no disease activity to 100=maximum disease activity). DAS28-ESR = 0.56\*square root (sqrt)(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*Patient's Global Assessment of Disease Activity. Total score range: 0-10, higher score=more disease activity. DAS28-ESR \<= 3.2 implied low disease activity (LDA) and DAS28-ESR \<2.6 = clinical remission.
Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)
Percentage of Participants With European League Against Rheumatism (EULAR) Response of 'Good' or 'Moderate'
DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and Physician's Global Assessment of Disease Activity (VAS: 0=no disease activity to 100=maximum disease activity). DAS28-ESR = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\*Patient's Global Assessment of Disease Activity. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline greater than (\>) 1.2 with a DAS28 score less than or equal to (≤) 3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 to less than or equal to (≤) 5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1.
Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at 24 Weeks Following Each Course
The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)
Change From Baseline in Total Rheumatoid Factors (RF) at 24 Weeks Following Each Course
Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)
Percentage of Participants Who Discontinued Treatment Due to Insufficient Response
Time frame: First, second, third, fourth, fifth, sixth, and seventh course of rituximab (up to a median of approximately 2, 62, 124, 186, 248, 310, and 372 weeks, respectively)
Time Since Last Treatment Course
Time since last treatment course = The last day of the last dose of rituximab to date of last contact. Date of last contact is the last available date of efficacy, complete medication start date, laboratory, adverse event assessments, early withdrawal visit, date of last contact, or date of death.
Time frame: Baseline up to 10 years
This study included participants who had previously participated in studies WA16291 (NCT02693210) or WA17043 (NCT00074438).
| Milestone | Rituximab |
|---|---|
| Started | 465 |
| Completed | 272 |
| Not completed | 193 |
| Withdrew: Adverse event | 26 |
| Withdrew: Death | 10 |
| Withdrew: Other | 157 |
A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in tender joint count (TJC) and swollen joint count (SJC) (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[visual analog scale (VAS): 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or erythrocyte sedimentation rate \[ESR\]). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
| percentage of participants | Rituximab |
|---|---|
| Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response After First Course | 67.1 |
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
| percentage of participants | Rituximab |
|---|---|
| Percentage of Participants With ACR20 Response After Second Course | 70.8 |
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
| percentage of participants | Rituximab |
|---|---|
| Percentage of Participants With ACR20 Response After Third Course | 73.2 |
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
| percentage of participants | Rituximab |
|---|---|
| Percentage of Participants With ACR20 Response After Fourth Course | 75.1 |
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
| percentage of participants | Rituximab |
|---|---|
| Percentage of Participants With ACR20 Response After Fifth Course | 69.7 |
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
| percentage of participants | Rituximab |
|---|---|
| Percentage of Participants With ACR20 Response After Sixth Course | 68.2 |
A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.
| percentage of participants | Rituximab |
|---|---|
| Percentage of Participants With ACR20 Response After Seventh Course | 59.5 |
A participant had an ACR50 and ACR70 response if there was at least a 50% or 70% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of disease activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (CRP or ESR). The ACR50 and ACR70 responses were compared to Baseline in the precursor studies WA16291 or WA17043.
| percentage of participants | Rituximab |
|---|---|
| ACR50: 24 weeks after first course | 39.4 |
| ACR50: 24 weeks after second course | 41.9 |
| ACR50: 24 weeks after third course | 44.8 |
| ACR50: 24 weeks after fourth course | 46.9 |
| ACR50: 24 weeks after fifth course | 40.0 |
| ACR50: 24 weeks after sixth course | 40.0 |
| ACR50: 24 weeks after seventh course | 36.5 |
| ACR70: 24 weeks after first course | 16.3 |
| ACR70: 24 weeks after second course | 21.6 |
| ACR70: 24 weeks after third course | 20.0 |
| ACR70: 24 weeks after fourth course | 20.0 |
| ACR70: 24 weeks after fifth course | 18.9 |
| ACR70: 24 weeks after sixth course | 20.9 |
| ACR70: 24 weeks after seventh course | 18.9 |
The ACRn is calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (patient's assessment of disease activity; patient's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value \[either CRP or ESR\]). The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA. ACRn scores were calculated considering the original baseline in the precursor studies WA16291 or WA17043.
| units on a scale | Rituximab |
|---|---|
| 24 weeks after first course | 31.07 ± 50.188 |
| 24 weeks after second course | 34.15 ± 58.769 |
| 24 weeks after third course | 36.93 ± 44.912 |
| 24 weeks after fourth course | 39.59 ± 39.393 |
| 24 weeks after fifth course | 33.76 ± 48.309 |
| 24 weeks after sixth course | 29.74 ± 57.197 |
| 24 weeks after seventh course | 24.87 ± 51.336 |
DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (millimeters per hour \[mm/hour\]), and Patient's Global Assessment of Disease Activity (VAS: 0=no disease activity to 100=maximum disease activity). DAS28-ESR = 0.56\*square root (sqrt)(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*Patient's Global Assessment of Disease Activity. Total score range: 0-10, higher score=more disease activity. DAS28-ESR \<= 3.2 implied low disease activity (LDA) and DAS28-ESR \<2.6 = clinical remission.
| percentage of participants | Rituximab |
|---|---|
| LDA: 24 weeks after first course | 24.3 |
| LDA: 24 weeks after second course | 30.1 |
| LDA: 24 weeks after third course | 29.3 |
| LDA: 24 weeks after fourth course | 28.0 |
| LDA: 24 weeks after fifth course | 23.8 |
| LDA: 24 weeks after sixth course | 27.3 |
| LDA: 24 weeks after seventh course | 24.7 |
| Remission: 24 weeks after first course | 11.3 |
| Remission: 24 weeks after second course | 16.8 |
| Remission: 24 weeks after third course | 17.1 |
| Remission: 24 weeks after fourth course | 15.7 |
| Remission: 24 weeks after fifth course | 15.7 |
| Remission: 24 weeks after sixth course | 17.3 |
| Remission: 24 weeks after seventh course | 13.7 |
DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and Physician's Global Assessment of Disease Activity (VAS: 0=no disease activity to 100=maximum disease activity). DAS28-ESR = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\*Patient's Global Assessment of Disease Activity. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline greater than (\>) 1.2 with a DAS28 score less than or equal to (≤) 3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 to less than or equal to (≤) 5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1.
| percentage of participants | Rituximab |
|---|---|
| Moderate: 24 weeks after first course | 57.8 |
| Moderate: 24 weeks after second course | 58.5 |
| Moderate: 24 weeks after third course | 59.5 |
| Moderate: 24 weeks after fourth course | 60.9 |
| Moderate: 24 weeks after fifth course | 62.1 |
| Moderate: 24 weeks after sixth course | 57.0 |
| Moderate: 24 weeks after seventh course | 60.0 |
| Good: 24 weeks after first course | 24.3 |
| Good: 24 weeks after second course | 30.4 |
| Good: 24 weeks after third course | 29.1 |
| Good: 24 weeks after fourth course | 27.9 |
| Good: 24 weeks after fifth course | 24.3 |
| Good: 24 weeks after sixth course | 27.1 |
| Good: 24 weeks after seventh course | 25.7 |
The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
| units on a scale | Rituximab |
|---|---|
| 24 weeks after first course | -0.51 ± 0.555 |
| 24 weeks after second course | -0.48 ± 0.556 |
| 24 weeks after third course | -0.43 ± 0.532 |
| 24 weeks after fourth course | -0.47 ± 0.529 |
| 24 weeks after fifth course | -0.44 ± 0.541 |
| 24 weeks after sixth course | -0.38 ± 0.600 |
| 24 weeks after seventh course | -0.37 ± 0.576 |
No measurements were reported for this outcome.
| percentage of participants | Rituximab |
|---|---|
| First course | 1.1 |
| Second course | 2.3 |
| Third course | 2.0 |
| Fourth course | 2.0 |
| Fifth course | 0.8 |
| Sixth course | 0.0 |
| Seventh course | 0.6 |
Time since last treatment course = The last day of the last dose of rituximab to date of last contact. Date of last contact is the last available date of efficacy, complete medication start date, laboratory, adverse event assessments, early withdrawal visit, date of last contact, or date of death.
| years | Rituximab |
|---|---|
| Time Since Last Treatment Course | 4.21 ± 2.234 |
Collected over Baseline up to approximately 11 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab | — | 230/465 (49.5%) | 422/465 (90.8%) |
| Placebo | — | 12/127 (9.4%) | 93/127 (73.2%) |
| Event | Rituximab | Placebo |
|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 19/465 | 1/127 |
| FallInjury, poisoning and procedural complications | 19/465 | 0/127 |
| PneumoniaInfections and infestations | 13/465 | 1/127 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 12/465 | 0/127 |
| Myocardial infarctionCardiac disorders | 9/465 | 0/127 |
| Urinary tract infectionInfections and infestations | 7/465 | 0/127 |
| Lower respiratory tract infectionInfections and infestations | 6/465 | 0/127 |
| Joint destructionMusculoskeletal and connective tissue disorders | 6/465 | 0/127 |
| Device dislocationGeneral disorders | 6/465 | 0/127 |
| CellulitisInfections and infestations | 5/465 | 0/127 |
| Event | Rituximab | Placebo |
|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 236/465 | 54/127 |
| Infusion related reactionGeneral disorders | 203/465 | 25/127 |
| Upper respiratory tract infectionInfections and infestations | 153/465 | 7/127 |
| NasopharyngitisInfections and infestations | 145/465 | 13/127 |
| BronchitisInfections and infestations | 108/465 | 6/127 |
| Urinary tract infectionInfections and infestations | 102/465 | 9/127 |
| HypertensionVascular disorders | 93/465 | 6/127 |
| DiarrhoeaGastrointestinal disorders | 85/465 | 9/127 |
| Back painMusculoskeletal and connective tissue disorders | 84/465 | 7/127 |
| HeadacheNervous system disorders | 82/465 | 9/127 |
Safety Population included all participants who received any part of an infusion of study medication under Study WA16855.
| Age, Continuous(years) | Rituximab |
|---|---|
| Mean | 51 ± 12.01 |
| Sex: Female, Male(Participants) | Rituximab |
|---|---|
| Female | 364 |
| Male | 101 |
The record gives a start of Aug 2002, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab